A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02412371 |
Recruitment Status :
Terminated
(Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC)
First Posted : April 9, 2015
Results First Posted : July 22, 2020
Last Update Posted : July 22, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study seeks to establish
- the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy (Phase 1 portion), and
- to assess whether the addition of oral veliparib versus placebo to paclitaxel/carboplatin-based chemoradiotherapy with paclitaxel/carboplatin consolidation will improve progression-free survival (PFS) in adults with Stage III non-small cell lung cancer (Phase 2 portion).
A strategy decision was made not to proceed to Phase 2 portion of this study due to change in standard of care.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer Stage III | Drug: Paclitaxel Drug: Placebo for Veliparib Drug: Carboplatin Drug: Veliparib Radiation: Radiotherapy | Phase 1 Phase 2 |
This was to be a 2-phase study consisting of
- A Phase 1, dose escalation study of veliparib to determine a RPTD for combination with concurrent paclitaxel/carboplatin-based CRT and paclitaxel/carboplatin-based consolidation chemotherapy; followed by
- A Phase 2, randomized, double-blinded study to determine whether veliparib improved outcome relative to placebo when added to paclitaxel/carboplatin based CRT followed by consolidation paclitaxel/carboplatin in adults with previously untreated Stage III NSCLC.
In the dose escalation phase (Phase 1) of the study participants will be assigned to ascending doses of veliparib in combination with carboplatin, paclitaxel, and thoracic radiotherapy for 7 weeks following a traditional "3 + 3" design. The first cohort of at least 3 - 6 participants will receive veliparib 60 mg twice a day (BID) throughout CRT. Dose limiting toxicity (DLT) events will be collected for each dosing cohort until a new dosing cohort is opened or until the RPTD is identified. Participants will also receive a consolidation dose of veliparib of 120 mg BID + carboplatin and paclitaxel for up to two 21-day cycles. Once the concurrent CRT RPTD is identified, an additional cohort will be enrolled to explore the tolerability of a consolidation dose of veliparib at 240 mg BID + carboplatin + paclitaxel for up to two 21-day cycles.
Following the dose escalation portion of the study, the RPTD will be determined by the sponsor and the Phase 2 portion of the study will begin with patient randomization in a 1:1:1 ratio to concurrent paclitaxel/carboplatin/radiotherapy/veliparib followed by consolidation paclitaxel/carboplatin/veliparib, concurrent paclitaxel/carboplatin/radiotherapy/veliparib followed by consolidation paclitaxel/carboplatin/placebo, or concurrent paclitaxel/carboplatin/radiotherapy/placebo followed by consolidation paclitaxel/carboplatin/placebo. Randomization will be stratified by tumor volume (≤ 90 versus > 90 cm³) and smoking history (current smoker versus former smoker versus never smoked).
Phase 2 was not carried out since during the study there was a change in standard of care for patients with newly diagnosed, unresectable Stage III NSCLC.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | In the dose escalation phase (Phase 1) of the study participants will be enrolled sequentially to receive ascending dose of veliparib in combination with carboplatin + paclitaxel + thoracic radiotherapy. In the Phase 2 portion of the study participants were to be randomized in a 1:1:1 ratio to one of three treatment arms. |
Masking: | None (Open Label) |
Masking Description: | All participants will be treated with open-label paclitaxel and carboplatin (Phase 1 and Phase 2). Participants in Phase 1 will be treated with open-label veliparib. In Phase 2, the Sponsor, Investigator, study site personnel and participant were to be be blinded to each participant's treatment with veliparib or placebo throughout the course of the study. |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC) |
Actual Study Start Date : | April 30, 2015 |
Actual Primary Completion Date : | August 5, 2019 |
Actual Study Completion Date : | August 5, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy
Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks. After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle. |
Drug: Paclitaxel
Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Carboplatin Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Veliparib Capsule for oral administration
Other Name: ABT-888 Radiation: Radiotherapy Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks |
Experimental: Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib
Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks. After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle. |
Drug: Paclitaxel
Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Carboplatin Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Veliparib Capsule for oral administration
Other Name: ABT-888 Radiation: Radiotherapy Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks |
Experimental: Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo
Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks. After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle. |
Drug: Paclitaxel
Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Placebo for Veliparib Capsule for oral administration Drug: Carboplatin Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Veliparib Capsule for oral administration
Other Name: ABT-888 Radiation: Radiotherapy Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks |
Active Comparator: Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo
Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks. After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle. |
Drug: Paclitaxel
Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Drug: Placebo for Veliparib Capsule for oral administration Drug: Carboplatin Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation) Radiation: Radiotherapy Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks |
- Number of Participants With Dose-limiting Toxicities (DLTs) [ Time Frame: For Cohorts 1 - 5, from the start of veliparib dosing through 28 days after RT completion or until initiation of consolidation CT, approx. 10 weeks; For Cohort 6, 21 days from start of consolidation CT or until the start of cycle 2 consolidation therapy. ]
DLTs were defined as the following events considered treatment-related by the Investigator, graded per Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
- Radiation-induced myelopathy/myelitis or ≥ Grade (G) 3 cardiac toxicity
- Radiation-related pneumonitis resulting in delay in RT, CT, or veliparib of >3 weeks or early discontinuation (DC) of RT (total dose <50 Gy)
- ≥G4 esophagitis or esophagitis, dysphagia, and odynophagia requiring treatment interruption of >7 days despite medical management, neutropenia for >7 days or neutropenic fever or thrombocytopenia
- ≥G2 seizure
- G4 diarrhea or nausea/vomiting despite antiemetic therapy for >48 hours
- Any other toxicity resulting in delay in RT, CT or veliparib >14 days or early DC of RT
- Other nonhematologic toxicities ≥G3, except anorexia, fatigue, G3 infection, G3 aspartate/alanine transferase (AST/ALT) elevations ≤7 days, infusion reactions, G3/4 lymphopenia or electrolyte abnormalities corrected to ≤G2 in <48 hours
- Objective Response Rate [ Time Frame: Tumor assessments were performed prior to consolidation chemotherapy, 24 weeks after start of treatment, every 8 weeks until 1 year after start of treatment, and then every 12 weeks until disease progression; median time on follow-up was 11 months. ]
Objective response rate (ORR) is defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR) as assessed by the investigator using RECIST v1.1. Participants who did not meet complete response or partial response, including those who did not have post-baseline radiological assessments were considered as non-responders.
Complete Response (CR): The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Response must have been confirmed 4 weeks after the first documentation.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants with histologically or cytologically confirmed Stage III non-small cell lung cancer (NSCLC).
- Participants in the randomized portion of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.
- Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to simulation) < 35%.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 - 1.
- Participant must have adequate hematologic, renal, hepatic, and lung function.
- Participant must consent to provide archived tissue or cytology sample of NSCLC lesion for analysis.
Exclusion Criteria:
- Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC. Participants curatively treated for past early stage NSCLC greater than 3 years ago may be included.
- Participants with prior exposure to poly-adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors.
- Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).
- Participants with prior mediastinal or thoracic radiotherapy. Prior tangential radiotherapy to prior breast cancer is acceptable.
- Participants with major surgery in the 4 weeks prior to randomization (Video-assisted thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).
- Participants with a previous or concurrent malignancy except for treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient received potentially curative treatment and has been disease-free for 3 years or is considered cured by the investigator if has been disease-free for less than 3 years.
- Participant is pregnant or lactating.
- Participant with sensory peripheral neuropathy of ≥ Grade 2 at baseline, unable to swallow medication, or participants with prior history of seizure within the prior 12 months.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02412371
United States, California | |
Ucsd /Id# 133037 | |
La Jolla, California, United States, 92093 | |
United States, Delaware | |
Christiana Care Health Service /ID# 133486 | |
Newark, Delaware, United States, 19713 | |
United States, Illinois | |
University of Chicago /ID# 133828 | |
Chicago, Illinois, United States, 60637-1443 | |
United States, Maryland | |
Univ Maryland School Medicine /ID# 132944 | |
Baltimore, Maryland, United States, 21201 | |
United States, Massachusetts | |
Dana-Farber Cancer Institute /ID# 133494 | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
SUNY Upstate Medical University - Downtown /ID# 133492 | |
Syracuse, New York, United States, 13210 | |
United States, North Carolina | |
Unc /Id# 133496 | |
Chapel Hill, North Carolina, United States, 27599 | |
Duke University Medical Center /ID# 133497 | |
Durham, North Carolina, United States, 27710-3000 | |
Wake Forest Univ HS /ID# 134608 | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Rhode Island | |
Rhode Island Hospital /ID# 133493 | |
Providence, Rhode Island, United States, 02903 | |
The Miriam Hospital /ID# 133910 | |
Providence, Rhode Island, United States, 02906 | |
United States, Virginia | |
University of Virginia /ID# 133495 | |
Charlottesville, Virginia, United States, 22908 |
Study Director: | AbbVie Inc. | AbbVie |
Responsible Party: | AbbVie |
ClinicalTrials.gov Identifier: | NCT02412371 |
Other Study ID Numbers: |
M14-360 2016-001659-32 ( EudraCT Number ) |
First Posted: | April 9, 2015 Key Record Dates |
Results First Posted: | July 22, 2020 |
Last Update Posted: | July 22, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. |
Access Criteria: | Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link. |
URL: | https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
veliparib PARP inhibitor ABT-888 first line previously untreated |
stage III non-small cell lung cancer radiotherapy paclitaxel carboplatin |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Paclitaxel |
Carboplatin Veliparib Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors |